ESTRO–ReCOG consensus prioritizes cumulative organ doses and daily imaging in lung reirradiation

New ESTRO–ReCOG guidance recommends validated cumulative dose assessment and daily volumetric image guidance, prioritizing critical organs during lung reirradiation.

KEY POINTS

  • This consensus guidance was developed by the ESTRO Reirradiation and Lung Focus Groups and the Reirradiation Collaborative Group (ReCOG), involving radiation oncologists, medical physicists, and radiation therapists from 14 European and North American centers. Recommendations were derived through a case-based survey and structured multidisciplinary discussions, focusing on technically robust, definitive-intent lung reirradiation rather than patient selection or prescription guidelines. The framework has been endorsed by the participating ESTRO focus groups and ReCOG.
  • Previous radiotherapy data should be retrieved and incorporated into every stage of retreatment planning, including prior treatment images, dose distributions, delivered fractions, setup conditions, and residual toxicities. Reproducing the original immobilization and respiratory management approach may improve registration accuracy, but alternative positioning or deep-inspiration breath-hold should be considered when clinically advantageous. Importantly, changing respiratory conditions between treatment courses can introduce substantial anatomical differences and compromise the reliability of cumulative dose assessment.
  • Three-dimensional accumulation of biologically equivalent dose is preferred whenever registration quality permits. Previous and current physical doses should be converted to a common radiobiological scale, such as BED or EQD2, before accumulation. Deformable image registration (DIR) is generally favored for volumetric dose evaluation, while organ-at-risk-focused rigid registration is an acceptable alternative when DIR is unreliable. Simple point-dose summation may be sufficient in low-complexity cases but can overestimate cumulative exposure, and adding DVH values from separate plans cannot reproduce a true cumulative DVH.
  • Registration accuracy must be assessed locally, particularly near steep dose gradients and critical structures. Atelectasis, pleural effusion, pulmonary edema, and changing respiratory conditions can make whole-thorax registration unreliable. The guidance recommends visual verification, sensitivity assessment using alternative registrations or geometric perturbations, and consideration of planning risk volumes when cumulative doses approach tolerance limits. Recalculating historical plans with contemporary dose algorithms is also advised when older heterogeneity corrections may affect accumulated dose estimates.
  • Treatment optimization should explicitly account for the remaining dose tolerance of individual OAR subvolumes. Previously delivered EQD2 distributions can guide avoidance structures and constrain the dose contributed by the new plan. In selected situations, accepting reduced target coverage near critical structures may be necessary to protect the bronchial tree, spinal cord, esophagus, or heart. The illustrative case received 66 Gy in 33 fractions, followed nine years later by 60 Gy in 30 fractions, with deliberate PTV undercoverage near the bronchus and heart.
  • Time-dependent normal-tissue recovery remains a major uncertainty. Although the illustrative REPAIR trial case applied a tissue recovery factor of 0.51, effectively reducing the previous dose contribution by 51% for cumulative OAR evaluation, the authors emphasize that such assumptions lack high-level experimental validation and are not generally recommended for routine use. Without applying recovery, the case's maximum bronchial dose would have reached 122 Gy EQD2, illustrating the substantial influence of recovery assumptions on clinical decision-making.
  • Daily volumetric image guidance is strongly recommended, with setup decisions focusing not only on target alignment but also on critical OARs approaching cumulative tolerance. CBCT should verify soft-tissue anatomy and identify changes that could shift previously irradiated structures into high-dose regions. In the illustrative case, a new pleural effusion was detected on day 3, increased by day 8, and required reassessment and drainage. The authors emphasize clear documentation of matching priorities, multidisciplinary communication, and adaptive reassessment when anatomical changes threaten the planned cumulative dose distribution.

CLINICAL TAKEAWAY

This ESTRO–ReCOG consensus offers a practical framework for implementing high-dose lung reirradiation, emphasizing validated cumulative dose assessment, individualized OAR-based optimization, and daily anatomical verification. The guidance is especially relevant to centers developing or refining thoracic reirradiation workflows, but its recommendations should not be interpreted as proof that specific registration methods, recovery factors, or target-coverage compromises improve clinical outcomes.

SOURCE

Radiotherapy and Oncology

Browse more research Suggest a correction